XORTX Therapeutics Inc. - צמיחת מכירות משנה לשנה ב-12 החודשים האחרונים XRTX

The industry R&D pipeline for hypouricemic agents maintains strong momentum. XORTX Therapeutics Inc. (XRTX) relies on Canadian development centers for targeted kidney therapy, while exclusive patents for XRx-008 block competitor access under strict FDA oversight. The TTM revenue growth rate compared to the same period last year visualizes the business expansion, with this metric equal to 0.00.
XORTX - פילוחים אנליטיים ומדדי מפתח (XRTX)

Steady confidence among nephrologists regarding the safety of XORTX Therapeutics Inc. (XRTX) products is reflected in the year-over-year (TTM) commercial revenue growth trend. This indicator measures the percentage change in sales over a rolling twelve-month period, stripping business expansion rates of seasonality and speculation, which allows investors to assess the issuer's true fundamental strength during economic cycle shifts.